Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401370 | 0.84 | L3MBTL1 (0.40) | PTGDR2KMT2AMEN1ALDH1A1 | |
| SCHEMBL6404808 | 0.84 | CASR (0.37) | CASRKAT6APTGDR2KMT2ANR1H4 | |
| SCHEMBL6404630 | 0.78 | L3MBTL1 (0.44) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL7258293 | 0.78 | L3MBTL1 (0.44) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL6407163 | 0.77 | CA1 (0.42) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL6409451 | 0.74 | KMT2A (0.40) | CASRPTGDR2KMT2AMEN1NR1H4 | |
| SCHEMBL6409442 | 0.71 | SLC7A5 (0.39) | CASRPTGDR2BACE1KMT2AMEN1 | |
| SCHEMBL5521753 | 0.70 | HDAC3 (0.41) | CASRKAT6ANR1H4KDM4EMAPT | |
| SCHEMBL6408723 | 0.70 | CA1 (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL7257821 | 0.70 | L3MBTL1 (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | CASR 1067/4885KAT6A 3383/4885PTGDR2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.